Eli Lilly Touts Over 30% of Oral Obesity New Starts at Morgan Stanley Event
Eli Lilly executives claim more than 30% of new starts in oral obesity treatments at a Morgan Stanley conference, an unverified figure with implications for peptide supply chains.